, Tracking Stock Market Picks
Enter Symbol:
Cellectar Biosciences Inc. (CLRB) [hlAlert]

up 109.45 %

Novelos Therapeutics (NVLT) rated Buy with price target $3 by Caris & Company

Posted on: Wednesday,  Dec 9, 2009  10:25 AM ET by Caris & Company

Caris & Company rated Buy Cellectar Biosciences Inc. (NASDAQ: CLRB) on 12/09/2009, when the stock price was $1.48.
Since then, Cellectar Biosciences Inc. has gained 109.46% as of 08/25/2015's recent price of $3.10.
If you would have followed this Caris & Company's recommendation on CLRB, you would have gained 109.45% of your investment in 2085 days.

Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the Company?s lead compound, is in Phase III development for treatment of lung cancer under a special protocol assessment and fast track. NOV-002 is also in Phase II development for treatment of early-stage breast cancer and chemotherapy-resistant ovarian cancer. NOV-205, Novelos? second compound, is in Phase Ib development for chronic hepatitis C non responders. Both compounds have completed clinical trials in humans and have been approved for use in Russia where they were originally developed.

Caris & Company, an investment bank created by a diverse group of leading Wall Street professionals. We are founded on the basic principle that Wall Street requires a different type of organization: One that offers objective, conflict-free research, acute focus on customer service, broad institutional coverage, and an unwavering commitment to increasing the value of our clients' portfolios. Quite simply, our goal is to generate solid investment ideas for our clients. We offer a unique, differentiated, conflict-free research perspective on large, mid, and small capitalization companies in four growth oriented verticals: Health Care, Technology, Energy, and Consumer.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/9/2009 10:25 AM Buy
1.48 6.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy